Back to Screener

Valion Bio, Inc. - Common stock (VBIO)

NASDAQ Nano Cap
$0.85
Market Cap: $3M
Data as of Mar 31, 2026 (TTM)

Investment Snapshot

  • Piotroski F-Score 2/9 — signs of financial weakness
  • Negative net margin (-2,857.7%) — currently unprofitable
  • Revenue declining 34% annually

Valion Bio, Inc. - Common stock (VBIO) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $3 million . Key value metrics: Piotroski F-Score 2 out of 9 .

Value Score

Key Metrics

P/E Ratio
EPS
$-3.82
Div. Yield
PEG Ratio
P/S Ratio
EV/EBITDA
ROE
ROA
Gross Margin
Op. Margin
Net Margin
Debt/Equity
Current Ratio
Data sourced from SEC EDGAR and Polygon.io. Methodology.

Valion Bio, Inc. - Common stock — Fundamental Analysis Summary

StockPik's composite Value Score for VBIO is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

VBIO reports a thin gross margin of 0.7% and a negative operating margin of -2,700.2%.

VBIO shows revenue declining at 34% year-over-year, with earnings declining at 57%.

How is the Value Score calculated?
Read our full methodology →
What is the Piotroski F-Score?
The 9-point financial health score explained, with worked examples →
Previous
VATE
Next
VBIX